Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Egyptian International Pharmaceutical Investments (CAI:PHAR) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Egyptian International Pharmaceutical Investments's EV-to-EBIT for today is
Egyptian International Pharmaceutical Investments's current Enterprise Value is E£24,067 Mil.
Egyptian International Pharmaceutical Investments's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£2,469 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Egyptian International Pharmaceutical Investments's EV-to-EBITDA for today is:
Egyptian International Pharmaceutical Investments's current Enterprise Value is E£24,067 Mil.
Egyptian International Pharmaceutical Investments's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£2,583 Mil.
Egyptian International Pharmaceutical Investments's current Enterprise Value is E£24,067 Mil.
Egyptian International Pharmaceutical Investments's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£7,391 Mil.
Egyptian International Pharmaceutical Investments's current Enterprise Value is E£24,067 Mil.
Egyptian International Pharmaceutical Investments's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£-845 Mil.
Egyptian International Pharmaceutical Investments's current Enterprise Value is E£24,067 Mil.
Egyptian International Pharmaceutical Investments's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£-2,270 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egyptian International Pharmaceutical Investments Enterprise Value Related Terms
Egyptian International Pharmaceutical Investments Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egyptian International Pharmaceutical Investments Enterprise Value Chart
Egyptian International Pharmaceutical Investments Annual Data
CAI:PHAR vs ZTS, UTHR, VTRS: Enterprise Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egyptian International Pharmaceutical Investments Enterprise Value vs Drug Manufacturers Industry
Egyptian International Pharmaceutical Investments Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of E£24,067 Mil mean?
Egyptian International Pharmaceutical Investments (CAI:PHAR) has a Enterprise Value of E£24,067 Mil as of Jul. 06, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Egyptian International Pharmaceutical Investments and its competitors.
Is Egyptian International Pharmaceutical Investments' Enterprise Value too high?
Egyptian International Pharmaceutical Investments' current Enterprise Value is E£24,067 Mil. Overall, Egyptian International Pharmaceutical Investments has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egyptian International Pharmaceutical Investments' Enterprise Value compare to ZTS and UTHR?
Egyptian International Pharmaceutical Investments' Enterprise Value of E£24,067 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Egyptian International Pharmaceutical Investments and its competitors. Egyptian International Pharmaceutical Investments's current Enterprise Value is E£24,067 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egyptian International Pharmaceutical Investments stock overvalued right now?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments (CAI:PHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is E£59.75, compared to a current price of E£88.87 — trading 48.7% above its estimated fair value. The current Enterprise Value is E£24,067 Mil. Egyptian International Pharmaceutical Investments' overall GF Score™ is 70/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Egyptian International Pharmaceutical Investments (CAI:PHAR), the current Enterprise Value is E£24,067 Mil as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued.
The current stock price of E£88.87 is trading 48.7% above its estimated GF Value™ of E£59.75.
GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.
Key valuation signals for CAI:PHAR:
Enterprise Value: E£24,067 Mil
GF Value™: E£59.75 vs. price of E£88.87 (48.7% above fair value)
No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egyptian International Pharmaceutical Investments Business Description
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
70GF Score
Get the complete analysis for CAI:PHAR
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:PHAR has been successfully added to your 
